作者
Alfredo B Cuéllar-Barboza, Susan L McElroy, Marin Veldic, Balwinder Singh, Simon Kung, Francisco Romo-Nava, Nicolas A Nunez, Alejandra Cabello-Arreola, Brandon J Coombes, Miguel Prieto, Hannah K Betcher, Katherine M Moore, Stacey J Winham, Joanna M Biernacka, Mark A Frye
发表日期
2020/12
来源
International Journal of Bipolar Disorders
卷号
8
页码范围
1-17
出版商
Springer Berlin Heidelberg
简介
Background
Treatment in bipolar disorder (BD) is commonly applied as a multimodal therapy based on decision algorithms that lack an integrative understanding of molecular mechanisms or a biomarker associated clinical outcome measure. Pharmacogenetics/genomics study the individual genetic variation associated with drug response. This selective review of pharmacogenomics and pharmacogenomic testing (PGT) in BD will focus on candidate genes and genome wide association studies of pharmacokinetic drug metabolism and pharmacodynamic drug response/adverse event, and the potential role of decision support tools that incorporate multiple genotype/phenotype drug recommendations.
Main body
We searched PubMed from January 2013 to May 2019, to identify studies reporting on BD and pharmacogenetics, pharmacogenomics and PGT. Studies were selected considering their contribution to the …
学术搜索中的文章
AB Cuéllar-Barboza, SL McElroy, M Veldic, B Singh… - International Journal of Bipolar Disorders, 2020